Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Argus Health
QuintilesIMS
Johnson and Johnson
Baxter
Cerilliant
Dow
Harvard Business School
Chinese Patent Office
Express Scripts

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,942,519

« Back to Dashboard

Which drugs does patent 5,942,519 protect, and when does it expire?

Patent 5,942,519 protects PROSCAR and is included in one NDA.

This patent has six patent family members in five countries.
Summary for Patent: 5,942,519
Title: Prevention of precipitated acute urinary retention
Abstract:This invention is concerned with the prevention of precipitated acute urinary retention in a subject male susceptible thereto by the administration of an inhibitor of 5.alpha.-reductase to the subject. The present invention also provides for a method of reducing the risk of precipitated acute urinary retention by the administration of a 5.alpha.-reductase inhibitor to the subject at risk therefor.
Inventor(s): Waldstreicher; Joanne (Scotch Plains, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/178,138
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 5,942,519

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck PROSCAR finasteride TABLET;ORAL 020180-001 Jun 19, 1992 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,942,519

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1279099 ➤ Try a Free Trial
Australia 731576 ➤ Try a Free Trial
Canada 2308070 ➤ Try a Free Trial
European Patent Office 1032400 ➤ Try a Free Trial
Japan 2001521000 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 9921563 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
McKinsey
Mallinckrodt
Farmers Insurance
AstraZeneca
US Army
Queensland Health
Express Scripts
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot